Michael J. Overman, MD | Authors

July 15, 2021

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

July 02, 2021

Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.

January 22, 2019

Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

November 13, 2018

Michael J. Overman, MD, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer.

March 07, 2017

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate-142 trial, which investigated nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer.

June 28, 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy as a treatment for patients with colorectal cancer.